Targeting the Microenvironment in Esophageal Cancer
Reads0
Chats0
TLDR
In this article, the authors summarized the microenvironment of esophageal cancer and the latest advances in microenvironment-targeting therapies in this review, and showed that TME is an important therapeutic target for EC and that many new drugs and therapies that have been developed to target microenvironment may become treatment options in the future.Abstract:
Esophageal cancer (EC) is the eighth most common type of cancer and the sixth leading cause of cancer-related deaths worldwide. At present, the clinical treatment for EC is based mainly on radical surgery, chemotherapy, and radiotherapy. However, due to the limited efficacy of conventional treatments and the serious adverse reactions, the outcome is still unsatisfactory (the 5-year survival rate for patients is less than 25%). Thus, it is extremely important and urgent to identify new therapeutic targets. The concept of tumor microenvironment (TME) has attracted increased attention since it was proposed. Recent studies have shown that TME is an important therapeutic target for EC. Microenvironment-targeting therapies such as immunotherapy and antiangiogenic therapy have played an indispensable role in prolonging survival and improving the prognosis of patients with EC. In addition, many new drugs and therapies that have been developed to target microenvironment may become treatment options in the future. We summarize the microenvironment of EC and the latest advances in microenvironment-targeting therapies in this review.read more
Citations
More filters
Journal ArticleDOI
IGFBP7 remodels the tumor microenvironment of esophageal squamous cell carcinoma by activating the TGFβ1/SMAD signaling pathway
TL;DR: Increased IGFBP7 may accelerate the progression of ESCC by upregulating TGF β1, α-SMA, and collagen I via activating the TGFβ1/SMAD signaling pathway, which could remodel the TME.
Journal ArticleDOI
The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma
TL;DR: This review will focus on the mechanism of different microenvironment cellular elements in ESCC invasion and metastasis and discuss recent therapeutic attempts to restore the tumor-suppressing function of cells within the TME.
Journal ArticleDOI
From NLR to TIN: What Can’t Neutrophils Tell Us About Prognosis in Resectable Esophageal Cancer?
Journal ArticleDOI
MAIP1-Related Tumor Immune Infiltration: As a Potential Prognostic Biomarker for Esophageal Cancer
TL;DR: It is proposed that MAIP1 overexpression was associated with poor prognosis and tumor immune infiltration in EC and further investigation is needed.
Journal ArticleDOI
Development and validation of a nomogram for patients with stage II/III gastric adenocarcinoma after radical surgery
TL;DR: Wang et al. as mentioned in this paper constructed nomograms based on clinicopathological features and routine preoperative hematological indices to predict cancer-specific survival (CSS) and disease-free survival (DFS) in patients with stage II/III gastric adenocarcinoma (GA) after radical resection.
References
More filters
Journal ArticleDOI
Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-κB
Parvaneh Rafiee,Victoria M. Nelson,Sharon Manley,Michael Wellner,Martin Floer,David G. Binion,Reza Shaker +6 more
TL;DR: IL-6 and IL-8 expression by acid may contribute to the pathobiology of mucosal injury in GERD, and inhibition of the NF-kappaB/proinflammatory cytokine pathways may emerge as important therapeutic targets for treatment of esophageal inflammation.
Journal ArticleDOI
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
Shinichi Kageyama,Hisashi Wada,Kei Muro,Yasumasa Niwa,Shugo Ueda,Hiroshi Miyata,Shuji Takiguchi,Sahoko Sugino,Yoshihiro Miyahara,Hiroaki Ikeda,Naoko Imai,Eiichi Sato,Tomomi Yamada,Masaharu Osako,Mami Ohnishi,Naozumi Harada,Tadashi Hishida,Yuichiro Doki,Hiroshi Shiku +18 more
TL;DR: The patients who received 200 μg of CHP-NY-ESO-1 survived longer than patients receiving 100 μg of Cholesteryl pullulan, even those who exhibited unresponsiveness to previous therapies or had higher tumor burdens, and suggested better survival benefits.
Journal ArticleDOI
The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma.
Haiyu Wang,Benchen Rao,Jiamin Lou,Jianhao Li,Zhenguo Liu,Ang Li,Guangying Cui,Zhigang Ren,Zujiang Yu +8 more
TL;DR: The HGF/c-Met axis promotes the onset, proliferation, invasion, and metastasis of HCC, and can serve as a biomarker for diagnosis and prognosis, as well as a therapeutic target for HCC.
Journal ArticleDOI
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Manish A. Shah,Jae Yong Cho,Iain Beehuat Tan,Niall C. Tebbutt,Chia Jui Yen,Alice Kang,David S. Shames,Lilian Bu,Yoon-Koo Kang +8 more
TL;DR: The addition of onartuzumab to mFOLFOX6 in gastric cancer did not improve efficacy in an unselected population or in a MET immunohistochemistry-positive population, highlighting the importance of correctly selecting biomarkers for targeted therapies.
Journal ArticleDOI
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang,Talia Golan,Laetitia Dahan,Siqing Fu,Victor Moreno,Keunchil Park,Ravit Geva,Filippo de Braud,Zev A. Wainberg,Martin Reck,Laura W. Goff,Naomi Laing,Gu Mi,Joana M Oliveira,Heather Wasserstrom,Chia-Chi Lin +15 more
TL;DR: The ramucirumab/durvalumab combination showed antitumour activity in all cohorts, particularly in patients with high PD-L1 expression, and exhibited manageable safety.